UT MD Andreson Cancer Center
Welcome,         Profile    Billing    Logout  
 63 Trials 
80 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Coleman, Robert E
GOG-0213, NCT00565851: Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark SGO 2015
Mar 2015 - Mar 2015: SGO 2015
Active, not recruiting
3
1052
Japan, US, RoW
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI), NRG Oncology
Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
04/19
01/28
Fanale, Michelle
NCT03011814: Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Active, not recruiting
1/2
38
US
Durvalumab, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
City of Hope Medical Center, National Cancer Institute (NCI)
Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Sezary Syndrome, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
07/25
07/26
Valero, Vicente
NRG-BR003, NCT02488967: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting
3
782
Canada, US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
10/26
10/26
OFSET, NCT05879926: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting
3
3960
Canada, US, RoW
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
NRG Oncology, National Cancer Institute (NCI)
Breast Cancer
01/32
07/34
NCT05035836: A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Recruiting
2
20
US
Zanidatamab, ZW25, Letrozole, Tamoxifen
M.D. Anderson Cancer Center, Zymeworks BC Inc.
Breast Cancer, HER2-positive
12/25
12/25
NCT03202316: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Active, not recruiting
2
35
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Eribulin, ER-086526, Laboratory Biomarker Analysis, Pharmacological Study
M.D. Anderson Cancer Center
Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
12/25
12/25
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 Vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
05/25
05/28
ADEPT, NCT04569747: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Recruiting
2
375
US
Pertuzumab+TRASTUZUMAB, PHESGO, ADJUVANT ENDOCRINE THERAPY, Letrozole, Anastrozole, Exemestane, Tamoxifen, Leuprolide, or other LHRH agonist (per investigator discretion)
Dana-Farber Cancer Institute, Genentech, Inc.
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
09/26
09/30
NCI-2018-01784, NCT00477100: Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients with Inflammatory or Invasive Breast Cancer

Recruiting
N/A
1200
US
Biospecimen Collection, Interview, Medical Chart Review, Chart Review, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Texas Appropriation for Rare and Aggressive diseases
Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Second Primary Malignant Neoplasm
04/30
04/30
Li, Jing
BRAVO, NCT05647915: Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD

Completed
4
337
RoW
Berberine plus lifestyle intervention, Placebo plus lifestyle intervention
China National Center for Cardiovascular Diseases
Obesity, Obesity, Abdominal, NAFLD
08/24
08/24
NCT06425120: Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

Not yet recruiting
4
240
RoW
Xuesaitong Soft Capsule, LixuwangⓇ, Placebo
China National Center for Cardiovascular Diseases
Coronary Heart Disease
12/24
12/24
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
NCT05965284: Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

Recruiting
4
40
RoW
Azathioprine, Telitacicept, Taiai for commercial name
Chinese SLE Treatment And Research Group
ANCA-associated Vasculitis, Maintenance Therapy
12/25
12/26
ABCD, NCT05749874: Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus

Not yet recruiting
4
6500
RoW
Berberine plus lifestyle intervention, Placebo plus lifestyle intervention
China National Center for Cardiovascular Diseases
PreDiabetes, Abdominal Obesity, Hypertension, Dyslipidemias
12/26
12/26
NCT05962840: Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

Recruiting
4
40
RoW
Telitacicept, Taiai for commercial name, Placebo of Telitacicept
Chinese SLE Treatment And Research Group, Peking Union Medical College Hospital
ANCA Associated Vasculitis
12/26
12/26
EHTASEOCCS, NCT03373058: Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery

Recruiting
3
310
RoW
Hyperthermic Intraperitoneal Chemotherapy, HIPEC, cytoreductive surgery, CRS, adjuvant chemotherapy, ACT
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University, Henan Provincial People's Hospital, Xiangya Hospital of Central South University, The Third Xiangya Hospital of Central South University, Peking University Cancer Hospital & Institute, Peking University People's Hospital, Cancer Hospital of Guizhou Province, Chinese PLA General Hospital, Hebei Medical University Fourth Hospital, The Second Hospital of Hebei Medical University, West China Second University Hospital, Peking Union Medical College Hospital, First Affiliated Hospital, Sun Yat-Sen University, Henan Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, The Third Affiliated Hospital of Guangzhou Medical University, Wuhan University, RenJi Hospital, Obstetrics & Gynecology Hospital of Fudan University, Southern Medical University, China, Fourth Affiliated Hospital of Guangxi Medical University, Shandong Cancer Hospital and Institute, Beijing Obstetrics and Gynecology Hospital, Chongqing University Cancer Hospital, Xinqiao Hospital of Chongqing, Wuhan Union Hospital, China, First Affiliated Hospital of Chongqing Medical University, Affiliated Cancer Hospital of Shantou University Medical College
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
07/21
07/23
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke

Recruiting
3
1380
RoW
Shuxuening Injection, Placebo
Beijing Tiantan Hospital
Ischemic Stroke, Acute
06/25
12/26
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

Recruiting
3
1380
RoW
Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin
Beijing Tiantan Hospital
Ischemic Stroke, Acute
12/25
12/26
RESIST, NCT06615726: Regular Physical Activity in Patients With Symptomatic Intracranial Arterial Stenosis

Recruiting
3
1300
RoW
Regular physical activity, Control group
Capital Medical University
Ischemic Stroke, Transient Ischemic Attack
09/25
08/26
NCT06837922: Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma

Recruiting
3
504
RoW
MG-K10/Placebo
Shanghai Mabgeek Biotech.Co.Ltd
Asthma
11/27
01/28
Be-CLEVER, NCT05976152: Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial

Recruiting
3
3200
RoW
dl-3-butylphthalide, DL-3-n-butylphthalide (NBP), dl-3-butylphthalide placebo, NBP placebo
Fudan University
Stroke, Post-stroke Cognitive Impairment (PSCI)
12/26
12/26
NCT01592968: Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients with Newly Diagnosed Non-melanoma Brain Metastases

Active, not recruiting
3
88
US
Cognitive Assessment, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
09/25
09/25
NHIPEC, NCT05246020: Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the Trial)

Recruiting
2
80
RoW
HIPEC, intravenous chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hyperthermic Intraperitoneal Chemotherapy, Neoadjuvant Chemotherapy
12/22
12/24
NCT02713269: Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

Active, not recruiting
2
60
US
Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Thermal Ablation Therapy, thermal ablation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Thyroid Gland Carcinoma
08/25
08/25
NCT06205927: Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer

Recruiting
2
77
RoW
Standard carbon ion beam radiotherapy, Carbon ion beam radiotherapy simultaneously dose boost
Jian Chen
Non-small Cell Lung Cancer
12/24
12/26
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Terminated
2
6
RoW
Infigratinib, BGJ398, BBP-831
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
NCT06186726: Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors

Recruiting
2
48
RoW
carbon ion radiotherapy
Jian Chen
Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
12/26
12/29
NCT06311981: Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

Recruiting
2
29
RoW
carbon ion radiotherapy, targeted therapy, single regimen chemotherapy in sequence with radiotherapy
Jian Chen
Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy, Radiotherapy Side Effect
06/25
06/26
NCT06311955: Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor

Recruiting
2
48
RoW
Carbon ion radiotherapy, combined with platinum-based regimen
Jian Chen
Thymic Epithelial Tumor, Radiotherapy Side Effect, Carbon Ion Radiotheray, Heavy Ion Radiotherapy
02/28
02/29
NCT06311968: The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor

Recruiting
2
55
RoW
Proton radiotherapy, combined platinum based chemotherapy
Jian Chen
Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity
02/27
02/27
AGE-M, NCT06459310: Pilot Study on Evaluating the Geroprotective Effect of Metformin

Recruiting
2
130
RoW
Metformin Hydrochloride tablet, Metformin, Placebo
Xuanwu Hospital, Beijing, Institute of Zoology, Chinese Academy of Sciences, Beijing Institute of Genomics, Chinese Academy of Sciences, Merck Serono Co., Ltd., China
Metformin, Aging
09/26
07/28
NCI-2018-01809, NCT01644591: Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

Active, not recruiting
2
49
US
Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
08/26
08/26
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Completed
2
305
RoW
SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan
Shanghai Pharmaceuticals Holding Co., Ltd
Diabetic Kidney Disease
12/24
12/24
NCT04516070: Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis

Active, not recruiting
2
55
US
Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/26
12/26
NCT05613452: Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer

Recruiting
2
43
RoW
Carbon ion beam radiotherapy
Shanghai Proton and Heavy Ion Center
Non-small Cell Lung Cancer
01/25
01/26
NCT06036966: The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients

Not yet recruiting
2
34
NA
Hetrombopag
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Thrombocytopenia
07/25
07/25
FRUSICA-1, NCT03903705: : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Completed
1/2
348
RoW
Fruquintinib in Combination with Sintilimab, Fruquintinib
Hutchmed
Advanced Solid Tumor
11/23
12/24
NCT05382910: A Study of MG-K10 in Subjects With Asthma

Recruiting
1/2
180
RoW
MG-K10, Placebo
Shanghai Mabgeek Biotech.Co.Ltd
Asthma
12/23
06/24
NCI-2016-00661, NCT02696993: Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

Active, not recruiting
1/2
80
US
Cognitive Assessment, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy
M.D. Anderson Cancer Center
Metastatic Malignant Neoplasm in the Brain, Stage IV Non-Small Cell Lung Cancer AJCC v7
12/24
12/24
NCT04592458: Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

Not yet recruiting
1
10
RoW
β-globin restored autologous HSC
BGI-research, Shenzhen Children's Hospital
β-Thalassemia Major
11/22
11/24
SAFE-APD, NCT03598387: Automated Peritoneal Dialysis Versus Intermittent Hemodialysis in Acute Kidney Injury

Recruiting
N/A
100
RoW
Automated peritoneal dialysis, Intermittent hemodialysis
Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation
Acute Kidney Injury
12/22
12/22
NCT04682795: Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM

Recruiting
N/A
200
RoW
Needle-free injector, Insulin pen
Second Affiliated Hospital, School of Medicine, Zhejiang University
T2DM (Type 2 Diabetes Mellitus), Needle-free Injector, Time in Range
12/22
12/22
ESPRIT, NCT04030234: Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs () Study

Completed
N/A
11255
RoW
Intensive BP treatment group, Control of SBP to <120 mmHg, Standard BP treatment group, Control of SBP to <140 mmHg
China National Center for Cardiovascular Diseases
Hypertension
06/23
07/23
NCT05352633: Effects of Intensive Systolic Blood Pressure Lowering Treatment on Out-of-office Blood Pressure - an Ancillary Study to Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study

Not yet recruiting
N/A
710
RoW
Intensive BP Arm, Control of SBP to <120 mmHg, Standard BP Arm, Control of SBP to <140 mmHg
China National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China
Blood Pressure
09/23
09/23
PERFECT, NCT06181552: Development of CV Risk Prediction Tools Based on AI and Fundus Imaging Technology Study

Not yet recruiting
N/A
1072
NA
fundus photograpgy, optical coherence tomography, OCT, optical coherence tomography angiography, OCT-A
China National Center for Cardiovascular Diseases, Beijing Tongren Hospital
Cardiovascular Diseases
03/25
06/25
FUTURE, NCT05459519: Effects of Dengzhanxixin Capsule on Platelet Function in Individuals at High Risk for Cardiovascular Disease

Recruiting
N/A
165
RoW
Dengzhanxixin Capsule plus Placebo Capsule, Placebo
China National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medial Sciences, Shenzhen, Shenzhen
Diabetes, Hypertension, Hypercholesterolemia
12/23
12/23
NCT05722275: Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

Recruiting
N/A
400
Europe, RoW
Peritoneal metastasis status ascertainment
Chinese Academy of Sciences, Peking University Cancer Hospital & Institute, Zhenjiang First People's Hospital, The First Affiliated Hospital of Zhengzhou University, Nanfang Hospital of Southern Medical University, Guizhou Provincial People's Hospital, Henan Cancer Hospital, Yunnan Cancer Hospital, Guangdong Provincial People's Hospital, Guangzhou Medical University, Fujian Medical University Union Hospital, Shanxi Province Cancer Hospital, Sun Yat-sen University, Beihang University, Scientific Institute San Raffaele
Gastric Cancer, Peritoneal Metastases
12/23
12/28
NCT06422052: Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspepsia Symptoms

Recruiting
N/A
2242
RoW
Epidemiological questionnaire and Functional Dyspepsia Symptom Diary（FDSD）
Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection, Dyspepsia
05/25
05/25
NutriConnect, NCT06263751: Comparing the Effectiveness of Two Produce Prescription Approaches On Fruit and Vegetable Intake and Food Security, While Exploring Implementation Outcomes Such as Reach, Implementation, Sustainability, and Cost

Recruiting
N/A
240
US
Product prescription program- NutriConnect Credit, Product prescription program- NutriConnect Delivery
Washington University School of Medicine, Schnuck Markets, Inc., BJC HealthCare
Food Insecurity
03/25
06/25
NCT06163092: Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent Miscarriage

Recruiting
N/A
175
RoW
Chinese University of Hong Kong
Recurrent Miscarriage
01/26
01/27
NCT06883487: Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary

Recruiting
N/A
144
RoW
No intervention
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Exploring HER2 Positive Diagnostic Criteria in High-grade Serous Ovarian Cancer, Observing the Effectiveness of Targeted HER2 ADC Drugs
03/27
03/27
NCT05783986: Developing a MRI-based Deep Learning Model to Predict MMR Status

Not yet recruiting
N/A
600
NA
randomly divided
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University
Endometrial Cancer
06/24
12/24
NCT06622798: Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients

Recruiting
N/A
470
RoW
Non-interventional
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Amoy Diagnostics Co., LTD
Exploring the Correlation of HRD Score Pairs with the Prognosis of Chinese Ovarian Cancer Patients and the Outcome of Maintenance Therapy with PARPi
01/25
07/26
NCT06035250: AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Recruiting
N/A
200
Europe, RoW
Neoadjuvant Chemotherapy
Chinese Academy of Sciences, Peking University Cancer Hospital & Institute, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Yunnan Cancer Hospital, Henan Cancer Hospital, Zhenjiang First People's Hospital, First Hospital of China Medical University, Cancer Hospital of Guangxi Medical University, Peking University People's Hospital, Tianjin Medical University Cancer Institute and Hospital, The First Affiliated Hospital of Zhengzhou University, Nanfang Hospital, Southern Medical University, The Affiliated Hospital of Qingdao University, Ruijin Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Peking Union Medical College Hospital, Xiangya Hospital of Central South University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The First Affiliated Hospital of Soochow University, First Affiliated Hospital, Sun Yat-Sen University, Fujian Medical University Union Hospital, Fujian Cancer Hospital, San Raffaele University Hospital, Italy
Gastric Cancer, Image, Pathology
08/24
12/29
BLESS, NCT05397535: Baduanjin Lower Elevated Blood PreSsure Study

Recruiting
N/A
216
RoW
Baduanjin, Brisk walking
China National Center for Cardiovascular Diseases
Elevated Blood Pressure
12/24
12/25
NCT05570071: A Study of the Use of Vaginal Radiofrequency Therapy in Treatment of SUI.

Not yet recruiting
N/A
90
NA
physical therapy
Qianfoshan Hospital
Urinary Incontinence, Stress
03/25
03/25
NCT06025045: Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments

Recruiting
N/A
50
RoW
Jing Li, Nanjing Shihejiyin Technology, Inc.
Ovarian Cancer Stage IV, Ovarian Cancer Stage III
08/25
08/25
CHAPERONE, NCT05965115: The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The Study

Recruiting
N/A
10000
RoW
Sample of Blood
Shanghai Zhongshan Hospital
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
08/25
08/35
NCT05613049: Confounding Factors of Chronic Endometritis in Women With Reproductive Failure

Recruiting
N/A
720
RoW
Chinese University of Hong Kong
IVF
07/27
01/28
NCT05153603: Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting

Not yet recruiting
N/A
50
NA
Olaparib mono-maintenance therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ovarian Neoplasms
09/22
12/22
NCT04527536: Research of Diagnostic Value for BMJ Infants

Not yet recruiting
N/A
300
NA
Neonatal hyperbilirubinemia
Shanghai First Maternity and Infant Hospital
Jaundice, Neonatal
09/22
09/22
Frumovitz, Michael
NCT03439085: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Checkmark From trial in combination with MEDI0457 for HPV associated recurrent/metastatic head and neck cancer at ASCO 2021
Jun 2021 - Jun 2021: From trial in combination with MEDI0457 for HPV associated recurrent/metastatic head and neck cancer at ASCO 2021
Terminated
2
41
US
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, INO 3112, INO-3112, INO-3112 Vaccine, MEDI 0457, MEDI-0457, MEDI0457, VGX-3100 Plus INO-9012, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Malignant Neoplasm, Recurrent Penile Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Refractory Malignant Neoplasm, Stage IV Anal Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8
09/22
09/22
NCT05063916: Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Active, not recruiting
2
18
US
AK104, Cadonilimab
M.D. Anderson Cancer Center
Carcinomas, Cervix Cancer, Cervical Cancer
08/25
08/25
HI-MOC, NCT05123807: Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer ( Study)

Recruiting
2
30
US
Cytoreductive surgery
M.D. Anderson Cancer Center
Ovarian Cancer
02/27
02/27
NECTUR, NCT04723095: Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

Recruiting
N/A
750
US
Follow-Up, Active Follow-up, Clinical Signs Follow-up, CLSFUP, Follow Up, Followed, Followup, Medical Chart Review, Chart Review
M.D. Anderson Cancer Center
Cervical Large Cell Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Cervical Small Cell Carcinoma, Cervical Undifferentiated Carcinoma, Stage I Cervical Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8
01/44
01/44
Brewster, Abenaa M
NCT02918474: Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Recruiting
N/A
15
US
Decision Aid, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Sporadic Breast Carcinoma
09/26
09/26
Amaria, Rodabe N
SUPRAME, NCT06743126: -ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting
3
360
US
IMA203, nivolumab plus relatlimab, Opdualag®, lifileucel, AMTAGVI, nivolumab, Opdivo®, pembrolizumab, Keytruda®, ipilimumab, Yervoy, Dacarbazine, DTIC-Dome, temozolomide, Temodar, paclitaxel, Taxol, paclitaxel plus carboplatin, Carbo/Taxol®, Albumin-Bound Paclitaxel, Abraxane®
Immatics US, Inc.
Melanoma, Cutaneous Malignant
01/28
10/31
NCT02519322: Neoadjuvant and Adjuvant Checkpoint Blockade

Completed
2
53
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Relatlimab, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Acral Lentiginous Melanoma AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
01/23
01/23
ALTER-PATH NeoDT, NCT04310397: Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Terminated
2
4
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Spartalizumab, PDR-001, PDR001, Therapeutic Conventional Surgery, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
10/23
10/23
Combi-Neo, NCT02231775: Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Active, not recruiting
2
58
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
04/27
04/27
NCT00338377: Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Active, not recruiting
2
1230
US
Dendritic Cell Immunization, Cyclophosphamide, Cytoxan, Neosar, Fludarabine, Fludarabine Phosphate, Fludara, T-Cells, Interleukin-2, IL-2, Proleukin, Mesna, Sodium 2-mercaptoethanesulfonate, Mesnum, Mesnex, NSC-113891, Intrathecal T-Cells, Intrathecal Interleukin-2
M.D. Anderson Cancer Center, Prometheus Laboratories, Key Biologics, LLC, National Cancer Institute (NCI), Adelson Medical Research
Melanoma
02/30
02/30
NCI-2014-02655, NCT01740557: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Completed
1/2
10
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, CXCR2-transduced Autologous TILs, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
04/23
04/23
NCT06237881: A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Active, not recruiting
1/2
15
US
KSQ-001EX, Interleukin-2, IL-2, Cyclophosphamide, Fludarabine
M.D. Anderson Cancer Center, KSQ Therapeutics, Inc.
Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms
01/27
01/29
NCT06598371: A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Recruiting
1/2
141
US
Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2, IL-2
M.D. Anderson Cancer Center, KSQ Therapeutics, Inc.
Select Advanced Solid Tumors
08/39
08/41
Agni-01, NCT06060613: Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Recruiting
1/2
52
US
OBX-115
Obsidian Therapeutics, Inc.
Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
10/25
10/27
Nautilus, NCT05340621: NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Completed
1/2
36
US
OKI-179 + binimetinib
OnKure, Inc.
RAS Mutation, NRAS Gene Mutation, Melanoma
01/25
01/25
NCT01955460: Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Active, not recruiting
1
34
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes, TGFbDNRII-transduced Autologous TILs
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
10/27
10/27
NCT05470283: Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Active, not recruiting
1
21
US
OBX-115, Acetazolamide, Cyclophosphamide, Cytoxan®, Neosar, Furosemide, Mesna, Fludarabine Phosphate, Fludarabine, Fludara
M.D. Anderson Cancer Center
Tumor, Metastatic Melanoma, Melanoma
04/27
04/27
Davies, Michael
No trials found
Parmar, Simrit
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Coleman, Robert E
GOG-0213, NCT00565851: Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark SGO 2015
Mar 2015 - Mar 2015: SGO 2015
Active, not recruiting
3
1052
Japan, US, RoW
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI), NRG Oncology
Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
04/19
01/28
Fanale, Michelle
NCT03011814: Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Active, not recruiting
1/2
38
US
Durvalumab, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
City of Hope Medical Center, National Cancer Institute (NCI)
Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Sezary Syndrome, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
07/25
07/26
Valero, Vicente
NRG-BR003, NCT02488967: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting
3
782
Canada, US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
10/26
10/26
OFSET, NCT05879926: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting
3
3960
Canada, US, RoW
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
NRG Oncology, National Cancer Institute (NCI)
Breast Cancer
01/32
07/34
NCT05035836: A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Recruiting
2
20
US
Zanidatamab, ZW25, Letrozole, Tamoxifen
M.D. Anderson Cancer Center, Zymeworks BC Inc.
Breast Cancer, HER2-positive
12/25
12/25
NCT03202316: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Active, not recruiting
2
35
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Eribulin, ER-086526, Laboratory Biomarker Analysis, Pharmacological Study
M.D. Anderson Cancer Center
Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
12/25
12/25
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 Vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
05/25
05/28
ADEPT, NCT04569747: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Recruiting
2
375
US
Pertuzumab+TRASTUZUMAB, PHESGO, ADJUVANT ENDOCRINE THERAPY, Letrozole, Anastrozole, Exemestane, Tamoxifen, Leuprolide, or other LHRH agonist (per investigator discretion)
Dana-Farber Cancer Institute, Genentech, Inc.
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
09/26
09/30
NCI-2018-01784, NCT00477100: Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients with Inflammatory or Invasive Breast Cancer

Recruiting
N/A
1200
US
Biospecimen Collection, Interview, Medical Chart Review, Chart Review, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Texas Appropriation for Rare and Aggressive diseases
Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Second Primary Malignant Neoplasm
04/30
04/30
Li, Jing
BRAVO, NCT05647915: Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD

Completed
4
337
RoW
Berberine plus lifestyle intervention, Placebo plus lifestyle intervention
China National Center for Cardiovascular Diseases
Obesity, Obesity, Abdominal, NAFLD
08/24
08/24
NCT06425120: Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

Not yet recruiting
4
240
RoW
Xuesaitong Soft Capsule, LixuwangⓇ, Placebo
China National Center for Cardiovascular Diseases
Coronary Heart Disease
12/24
12/24
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
NCT05965284: Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

Recruiting
4
40
RoW
Azathioprine, Telitacicept, Taiai for commercial name
Chinese SLE Treatment And Research Group
ANCA-associated Vasculitis, Maintenance Therapy
12/25
12/26
ABCD, NCT05749874: Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus

Not yet recruiting
4
6500
RoW
Berberine plus lifestyle intervention, Placebo plus lifestyle intervention
China National Center for Cardiovascular Diseases
PreDiabetes, Abdominal Obesity, Hypertension, Dyslipidemias
12/26
12/26
NCT05962840: Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

Recruiting
4
40
RoW
Telitacicept, Taiai for commercial name, Placebo of Telitacicept
Chinese SLE Treatment And Research Group, Peking Union Medical College Hospital
ANCA Associated Vasculitis
12/26
12/26
EHTASEOCCS, NCT03373058: Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery

Recruiting
3
310
RoW
Hyperthermic Intraperitoneal Chemotherapy, HIPEC, cytoreductive surgery, CRS, adjuvant chemotherapy, ACT
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University, Henan Provincial People's Hospital, Xiangya Hospital of Central South University, The Third Xiangya Hospital of Central South University, Peking University Cancer Hospital & Institute, Peking University People's Hospital, Cancer Hospital of Guizhou Province, Chinese PLA General Hospital, Hebei Medical University Fourth Hospital, The Second Hospital of Hebei Medical University, West China Second University Hospital, Peking Union Medical College Hospital, First Affiliated Hospital, Sun Yat-Sen University, Henan Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, The Third Affiliated Hospital of Guangzhou Medical University, Wuhan University, RenJi Hospital, Obstetrics & Gynecology Hospital of Fudan University, Southern Medical University, China, Fourth Affiliated Hospital of Guangxi Medical University, Shandong Cancer Hospital and Institute, Beijing Obstetrics and Gynecology Hospital, Chongqing University Cancer Hospital, Xinqiao Hospital of Chongqing, Wuhan Union Hospital, China, First Affiliated Hospital of Chongqing Medical University, Affiliated Cancer Hospital of Shantou University Medical College
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
07/21
07/23
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke

Recruiting
3
1380
RoW
Shuxuening Injection, Placebo
Beijing Tiantan Hospital
Ischemic Stroke, Acute
06/25
12/26
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

Recruiting
3
1380
RoW
Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin
Beijing Tiantan Hospital
Ischemic Stroke, Acute
12/25
12/26
RESIST, NCT06615726: Regular Physical Activity in Patients With Symptomatic Intracranial Arterial Stenosis

Recruiting
3
1300
RoW
Regular physical activity, Control group
Capital Medical University
Ischemic Stroke, Transient Ischemic Attack
09/25
08/26
NCT06837922: Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma

Recruiting
3
504
RoW
MG-K10/Placebo
Shanghai Mabgeek Biotech.Co.Ltd
Asthma
11/27
01/28
Be-CLEVER, NCT05976152: Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial

Recruiting
3
3200
RoW
dl-3-butylphthalide, DL-3-n-butylphthalide (NBP), dl-3-butylphthalide placebo, NBP placebo
Fudan University
Stroke, Post-stroke Cognitive Impairment (PSCI)
12/26
12/26
NCT01592968: Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients with Newly Diagnosed Non-melanoma Brain Metastases

Active, not recruiting
3
88
US
Cognitive Assessment, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
09/25
09/25
NHIPEC, NCT05246020: Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the Trial)

Recruiting
2
80
RoW
HIPEC, intravenous chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hyperthermic Intraperitoneal Chemotherapy, Neoadjuvant Chemotherapy
12/22
12/24
NCT02713269: Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

Active, not recruiting
2
60
US
Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Thermal Ablation Therapy, thermal ablation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Thyroid Gland Carcinoma
08/25
08/25
NCT06205927: Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer

Recruiting
2
77
RoW
Standard carbon ion beam radiotherapy, Carbon ion beam radiotherapy simultaneously dose boost
Jian Chen
Non-small Cell Lung Cancer
12/24
12/26
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Terminated
2
6
RoW
Infigratinib, BGJ398, BBP-831
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
NCT06186726: Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors

Recruiting
2
48
RoW
carbon ion radiotherapy
Jian Chen
Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
12/26
12/29
NCT06311981: Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

Recruiting
2
29
RoW
carbon ion radiotherapy, targeted therapy, single regimen chemotherapy in sequence with radiotherapy
Jian Chen
Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy, Radiotherapy Side Effect
06/25
06/26
NCT06311955: Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor

Recruiting
2
48
RoW
Carbon ion radiotherapy, combined with platinum-based regimen
Jian Chen
Thymic Epithelial Tumor, Radiotherapy Side Effect, Carbon Ion Radiotheray, Heavy Ion Radiotherapy
02/28
02/29
NCT06311968: The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor

Recruiting
2
55
RoW
Proton radiotherapy, combined platinum based chemotherapy
Jian Chen
Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity
02/27
02/27
AGE-M, NCT06459310: Pilot Study on Evaluating the Geroprotective Effect of Metformin

Recruiting
2
130
RoW
Metformin Hydrochloride tablet, Metformin, Placebo
Xuanwu Hospital, Beijing, Institute of Zoology, Chinese Academy of Sciences, Beijing Institute of Genomics, Chinese Academy of Sciences, Merck Serono Co., Ltd., China
Metformin, Aging
09/26
07/28
NCI-2018-01809, NCT01644591: Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

Active, not recruiting
2
49
US
Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
08/26
08/26
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Completed
2
305
RoW
SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan
Shanghai Pharmaceuticals Holding Co., Ltd
Diabetic Kidney Disease
12/24
12/24
NCT04516070: Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis

Active, not recruiting
2
55
US
Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/26
12/26
NCT05613452: Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer

Recruiting
2
43
RoW
Carbon ion beam radiotherapy
Shanghai Proton and Heavy Ion Center
Non-small Cell Lung Cancer
01/25
01/26
NCT06036966: The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients

Not yet recruiting
2
34
NA
Hetrombopag
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Thrombocytopenia
07/25
07/25
FRUSICA-1, NCT03903705: : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Completed
1/2
348
RoW
Fruquintinib in Combination with Sintilimab, Fruquintinib
Hutchmed
Advanced Solid Tumor
11/23
12/24
NCT05382910: A Study of MG-K10 in Subjects With Asthma

Recruiting
1/2
180
RoW
MG-K10, Placebo
Shanghai Mabgeek Biotech.Co.Ltd
Asthma
12/23
06/24
NCI-2016-00661, NCT02696993: Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

Active, not recruiting
1/2
80
US
Cognitive Assessment, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy
M.D. Anderson Cancer Center
Metastatic Malignant Neoplasm in the Brain, Stage IV Non-Small Cell Lung Cancer AJCC v7
12/24
12/24
NCT04592458: Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

Not yet recruiting
1
10
RoW
β-globin restored autologous HSC
BGI-research, Shenzhen Children's Hospital
β-Thalassemia Major
11/22
11/24
SAFE-APD, NCT03598387: Automated Peritoneal Dialysis Versus Intermittent Hemodialysis in Acute Kidney Injury

Recruiting
N/A
100
RoW
Automated peritoneal dialysis, Intermittent hemodialysis
Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation
Acute Kidney Injury
12/22
12/22
NCT04682795: Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM

Recruiting
N/A
200
RoW
Needle-free injector, Insulin pen
Second Affiliated Hospital, School of Medicine, Zhejiang University
T2DM (Type 2 Diabetes Mellitus), Needle-free Injector, Time in Range
12/22
12/22
ESPRIT, NCT04030234: Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs () Study

Completed
N/A
11255
RoW
Intensive BP treatment group, Control of SBP to <120 mmHg, Standard BP treatment group, Control of SBP to <140 mmHg
China National Center for Cardiovascular Diseases
Hypertension
06/23
07/23
NCT05352633: Effects of Intensive Systolic Blood Pressure Lowering Treatment on Out-of-office Blood Pressure - an Ancillary Study to Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study

Not yet recruiting
N/A
710
RoW
Intensive BP Arm, Control of SBP to <120 mmHg, Standard BP Arm, Control of SBP to <140 mmHg
China National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China
Blood Pressure
09/23
09/23
PERFECT, NCT06181552: Development of CV Risk Prediction Tools Based on AI and Fundus Imaging Technology Study

Not yet recruiting
N/A
1072
NA
fundus photograpgy, optical coherence tomography, OCT, optical coherence tomography angiography, OCT-A
China National Center for Cardiovascular Diseases, Beijing Tongren Hospital
Cardiovascular Diseases
03/25
06/25
FUTURE, NCT05459519: Effects of Dengzhanxixin Capsule on Platelet Function in Individuals at High Risk for Cardiovascular Disease

Recruiting
N/A
165
RoW
Dengzhanxixin Capsule plus Placebo Capsule, Placebo
China National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medial Sciences, Shenzhen, Shenzhen
Diabetes, Hypertension, Hypercholesterolemia
12/23
12/23
NCT05722275: Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

Recruiting
N/A
400
Europe, RoW
Peritoneal metastasis status ascertainment
Chinese Academy of Sciences, Peking University Cancer Hospital & Institute, Zhenjiang First People's Hospital, The First Affiliated Hospital of Zhengzhou University, Nanfang Hospital of Southern Medical University, Guizhou Provincial People's Hospital, Henan Cancer Hospital, Yunnan Cancer Hospital, Guangdong Provincial People's Hospital, Guangzhou Medical University, Fujian Medical University Union Hospital, Shanxi Province Cancer Hospital, Sun Yat-sen University, Beihang University, Scientific Institute San Raffaele
Gastric Cancer, Peritoneal Metastases
12/23
12/28
NCT06422052: Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspepsia Symptoms

Recruiting
N/A
2242
RoW
Epidemiological questionnaire and Functional Dyspepsia Symptom Diary（FDSD）
Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection, Dyspepsia
05/25
05/25
NutriConnect, NCT06263751: Comparing the Effectiveness of Two Produce Prescription Approaches On Fruit and Vegetable Intake and Food Security, While Exploring Implementation Outcomes Such as Reach, Implementation, Sustainability, and Cost

Recruiting
N/A
240
US
Product prescription program- NutriConnect Credit, Product prescription program- NutriConnect Delivery
Washington University School of Medicine, Schnuck Markets, Inc., BJC HealthCare
Food Insecurity
03/25
06/25
NCT06163092: Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent Miscarriage

Recruiting
N/A
175
RoW
Chinese University of Hong Kong
Recurrent Miscarriage
01/26
01/27
NCT06883487: Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary

Recruiting
N/A
144
RoW
No intervention
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Exploring HER2 Positive Diagnostic Criteria in High-grade Serous Ovarian Cancer, Observing the Effectiveness of Targeted HER2 ADC Drugs
03/27
03/27
NCT05783986: Developing a MRI-based Deep Learning Model to Predict MMR Status

Not yet recruiting
N/A
600
NA
randomly divided
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University
Endometrial Cancer
06/24
12/24
NCT06622798: Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients

Recruiting
N/A
470
RoW
Non-interventional
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Amoy Diagnostics Co., LTD
Exploring the Correlation of HRD Score Pairs with the Prognosis of Chinese Ovarian Cancer Patients and the Outcome of Maintenance Therapy with PARPi
01/25
07/26
NCT06035250: AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Recruiting
N/A
200
Europe, RoW
Neoadjuvant Chemotherapy
Chinese Academy of Sciences, Peking University Cancer Hospital & Institute, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Yunnan Cancer Hospital, Henan Cancer Hospital, Zhenjiang First People's Hospital, First Hospital of China Medical University, Cancer Hospital of Guangxi Medical University, Peking University People's Hospital, Tianjin Medical University Cancer Institute and Hospital, The First Affiliated Hospital of Zhengzhou University, Nanfang Hospital, Southern Medical University, The Affiliated Hospital of Qingdao University, Ruijin Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Peking Union Medical College Hospital, Xiangya Hospital of Central South University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The First Affiliated Hospital of Soochow University, First Affiliated Hospital, Sun Yat-Sen University, Fujian Medical University Union Hospital, Fujian Cancer Hospital, San Raffaele University Hospital, Italy
Gastric Cancer, Image, Pathology
08/24
12/29
BLESS, NCT05397535: Baduanjin Lower Elevated Blood PreSsure Study

Recruiting
N/A
216
RoW
Baduanjin, Brisk walking
China National Center for Cardiovascular Diseases
Elevated Blood Pressure
12/24
12/25
NCT05570071: A Study of the Use of Vaginal Radiofrequency Therapy in Treatment of SUI.

Not yet recruiting
N/A
90
NA
physical therapy
Qianfoshan Hospital
Urinary Incontinence, Stress
03/25
03/25
NCT06025045: Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments

Recruiting
N/A
50
RoW
Jing Li, Nanjing Shihejiyin Technology, Inc.
Ovarian Cancer Stage IV, Ovarian Cancer Stage III
08/25
08/25
CHAPERONE, NCT05965115: The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The Study

Recruiting
N/A
10000
RoW
Sample of Blood
Shanghai Zhongshan Hospital
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
08/25
08/35
NCT05613049: Confounding Factors of Chronic Endometritis in Women With Reproductive Failure

Recruiting
N/A
720
RoW
Chinese University of Hong Kong
IVF
07/27
01/28
NCT05153603: Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting

Not yet recruiting
N/A
50
NA
Olaparib mono-maintenance therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ovarian Neoplasms
09/22
12/22
NCT04527536: Research of Diagnostic Value for BMJ Infants

Not yet recruiting
N/A
300
NA
Neonatal hyperbilirubinemia
Shanghai First Maternity and Infant Hospital
Jaundice, Neonatal
09/22
09/22
Frumovitz, Michael
NCT03439085: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Checkmark From trial in combination with MEDI0457 for HPV associated recurrent/metastatic head and neck cancer at ASCO 2021
Jun 2021 - Jun 2021: From trial in combination with MEDI0457 for HPV associated recurrent/metastatic head and neck cancer at ASCO 2021
Terminated
2
41
US
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, INO 3112, INO-3112, INO-3112 Vaccine, MEDI 0457, MEDI-0457, MEDI0457, VGX-3100 Plus INO-9012, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Malignant Neoplasm, Recurrent Penile Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Refractory Malignant Neoplasm, Stage IV Anal Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8
09/22
09/22
NCT05063916: Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Active, not recruiting
2
18
US
AK104, Cadonilimab
M.D. Anderson Cancer Center
Carcinomas, Cervix Cancer, Cervical Cancer
08/25
08/25
HI-MOC, NCT05123807: Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer ( Study)

Recruiting
2
30
US
Cytoreductive surgery
M.D. Anderson Cancer Center
Ovarian Cancer
02/27
02/27
NECTUR, NCT04723095: Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

Recruiting
N/A
750
US
Follow-Up, Active Follow-up, Clinical Signs Follow-up, CLSFUP, Follow Up, Followed, Followup, Medical Chart Review, Chart Review
M.D. Anderson Cancer Center
Cervical Large Cell Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Cervical Small Cell Carcinoma, Cervical Undifferentiated Carcinoma, Stage I Cervical Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8
01/44
01/44
Brewster, Abenaa M
NCT02918474: Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Recruiting
N/A
15
US
Decision Aid, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Sporadic Breast Carcinoma
09/26
09/26
Amaria, Rodabe N
SUPRAME, NCT06743126: -ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting
3
360
US
IMA203, nivolumab plus relatlimab, Opdualag®, lifileucel, AMTAGVI, nivolumab, Opdivo®, pembrolizumab, Keytruda®, ipilimumab, Yervoy, Dacarbazine, DTIC-Dome, temozolomide, Temodar, paclitaxel, Taxol, paclitaxel plus carboplatin, Carbo/Taxol®, Albumin-Bound Paclitaxel, Abraxane®
Immatics US, Inc.
Melanoma, Cutaneous Malignant
01/28
10/31
NCT02519322: Neoadjuvant and Adjuvant Checkpoint Blockade

Completed
2
53
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Relatlimab, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Acral Lentiginous Melanoma AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
01/23
01/23
ALTER-PATH NeoDT, NCT04310397: Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Terminated
2
4
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Spartalizumab, PDR-001, PDR001, Therapeutic Conventional Surgery, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
10/23
10/23
Combi-Neo, NCT02231775: Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Active, not recruiting
2
58
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
04/27
04/27
NCT00338377: Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Active, not recruiting
2
1230
US
Dendritic Cell Immunization, Cyclophosphamide, Cytoxan, Neosar, Fludarabine, Fludarabine Phosphate, Fludara, T-Cells, Interleukin-2, IL-2, Proleukin, Mesna, Sodium 2-mercaptoethanesulfonate, Mesnum, Mesnex, NSC-113891, Intrathecal T-Cells, Intrathecal Interleukin-2
M.D. Anderson Cancer Center, Prometheus Laboratories, Key Biologics, LLC, National Cancer Institute (NCI), Adelson Medical Research
Melanoma
02/30
02/30
NCI-2014-02655, NCT01740557: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Completed
1/2
10
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, CXCR2-transduced Autologous TILs, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
04/23
04/23
NCT06237881: A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Active, not recruiting
1/2
15
US
KSQ-001EX, Interleukin-2, IL-2, Cyclophosphamide, Fludarabine
M.D. Anderson Cancer Center, KSQ Therapeutics, Inc.
Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms
01/27
01/29
NCT06598371: A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Recruiting
1/2
141
US
Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2, IL-2
M.D. Anderson Cancer Center, KSQ Therapeutics, Inc.
Select Advanced Solid Tumors
08/39
08/41
Agni-01, NCT06060613: Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Recruiting
1/2
52
US
OBX-115
Obsidian Therapeutics, Inc.
Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
10/25
10/27
Nautilus, NCT05340621: NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Completed
1/2
36
US
OKI-179 + binimetinib
OnKure, Inc.
RAS Mutation, NRAS Gene Mutation, Melanoma
01/25
01/25
NCT01955460: Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Active, not recruiting
1
34
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes, TGFbDNRII-transduced Autologous TILs
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
10/27
10/27
NCT05470283: Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Active, not recruiting
1
21
US
OBX-115, Acetazolamide, Cyclophosphamide, Cytoxan®, Neosar, Furosemide, Mesna, Fludarabine Phosphate, Fludarabine, Fludara
M.D. Anderson Cancer Center
Tumor, Metastatic Melanoma, Melanoma
04/27
04/27
Davies, Michael
No trials found
Parmar, Simrit
No trials found

Download Options